Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Kidneys Rebuilt in Lab May Offer Human Transplant Path

Don't Miss Out —
Follow us on:
Rat Kidneys Regenerated in Lab May Offer Human Transplant Path
A baby giant African pouch rat looks for its reward in an opening of a lab training box. Photographer: Yasuyoshi Chiba/AFP/Getty Images

April 15 (Bloomberg) -- Scientists have found a way to rebuild rat kidneys in the laboratory that successfully filtered blood and allowed the animals to urinate, an early research step that may one day lead to replacement organs for humans.

Researchers at Massachusetts General Hospital in Boston stripped donor organs of kidney cells with a chemical bath, leaving a physical scaffold behind made up largely of proteins. They then repopulated the structure with cells from both newborn rats and humans, and allowed the cells to grow in an incubator.

While the resulting organs weren’t as efficient as natural ones, they kept the kidney’s physical shape allowing transplant, the study reported. The work, published in the journal Nature Medicine, outlines a process that may one day be used to rebuild kidneys for people in renal failure, said Harald Ott, the study’s senior author. As many as 10 percent of about 100,000 Americans awaiting a kidney transplant as of April 5 will die before getting a transplant, the authors wrote.

“The resulting graft can be transplanted just like a donor kidney,” Ott said in a statement. “If this technology can be scaled to human-sized grafts, patients suffering from renal failure who are currently waiting for donor kidneys or who are not transplant candidates could theoretically receive new organs derived from their own cells.”

About 1 million people have end-stage renal disease, mostly caused when their kidneys are damaged by high blood pressure and diabetes, according to the U.S. Centers for Disease Control and Prevention in Atlanta. While dialysis can help these patients survive, only a transplant can cure the disease.

This isn’t the only approach to artificial kidneys. In April 2012, the U.S. Food and Drug Association picked a wearable artificial kidney device made by Blood Purification Technologies Inc. for its fast-track program. Research groups in Singapore and at the University of Michigan are working on other cell-based approaches.

To contact the reporter on this story: Elizabeth Lopatto in San Francisco at elopatto@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.